Type 2 diabetes: evidence beyond perception
- Treating type 2 diabetes: the gap between perception and evidence
D. R. Matthews, United Kingdom
- Type 2 diabetes recommendations: the move toward an evidence informed consensus
S. Colagiuri, Australia
- From randomized clinical trials to registry analysis: where is the evidence?
M. D. Khalangot, Ukraine
- Should there be evidence-based management for all ethnic groups of diabetics or not? Management beyond borders—an Asian perspective
S. P. Chan, Malaysia
- Should there be evidence-based management for all ethnic groups of diabetics or not? Management beyond borders—a South American perspective
R. O. Moreira, Brazil
- Diabetes education – key principles of individual or group participation
A. J. Sinclair, United Kingdom
- Outcome trials on the effects of glycemic control on cardiovascular risk in type 2 diabetes mellitus—What do we know and what will we learn from the ongoing trials?
L. A. Leiter, Canada
- Glucose lowering and kidney protection: can we hit 2 birds with 1 stone?
M. E. Cooper Australia
- The legacy effect in type 2 diabetes: fact or fiction?
M. Marre, France
- ADVANCE-ON*: current status *Action in Diabetes and Vascular disease PreterAx and DiamicroN MR Controlled Evaluation posttrial ObservatioNal study
S. Zoungas, J. Chalmers, Australia
- HbA1c targets: does one size fit all or should they be tailored to individual patients?
B. Bauduceau, France – F. Carrilho, Portugal – L. Czupryniak, Poland – N. Ghannam, Saudi Arabia – L. Litwak, Argentina – B. Mankovsky, Ukraine – M. Mota, D. Protasiewicz, S. G. Popa, Romania – A. Orabi, Egypt – U. Phadke, India – M. V. Shestakova, Russia – L. Smircic-
Duvnjak, Croatia – B. Tschiedel, Brazil – Z. Visockiene, Lithuania
- Diamicron (gliclazide) MR: the secretagogue with clinical benefits beyond insulin secretion
M. Ruiz, France
- How can today’s evidence-based proof in type 2 diabetes help us contain the diabetes epidemic?
Sir M. Hirst, United Kingdom
- The ADVANCE risk engine for cardiovascular disease prediction in the context of current strategies for cardiovascular risk evaluation in people with diabetes
A. P. Kengne, South Africa and Australia